GlyTR Therapeutics is a biotech company creating a new class of anti‑cancer immunotherapies that combine bispecific protein drugs with chimeric antigen receptor T‑cell (CAR‑T) platforms. Their technology targets cancer‑specific antigens that are abnormally expressed across a wide range of solid and blood cancers, enabling a single therapeutic to attack multiple tumor types such as breast cancer and leukemia. By addressing the limitations of existing antibody‑based treatments, GlyTR aims to deliver more precise and effective cancer killing.
Funding
Funding not disclosed
Founders
Product
Problem
Current antibody‑based cancer therapies are limited by a scarcity of shared tumor antigens, off‑target binding to normal tissues, and an inability to address the diversity of solid and hematologic malignancies with a single agent.
Solution
GlyTR Therapeutics has created a platform that generates both bispecific protein therapeutics and chimeric antigen receptor T‑cell (CAR‑T) products targeting protein markers that are abnormally expressed across a broad spectrum of cancers. By focusing on shared, cancer‑specific antigens, the platform enables a single therapeutic to recognize and kill multiple tumor types while minimizing on‑target, off‑tumor toxicity. The bispecific proteins simultaneously engage a tumor antigen and an immune effector cell, whereas the CAR‑T cells are engineered to express receptors that bind the same antigens, providing complementary mechanisms of action. This approach seeks to overcome the limitations of conventional antibodies and deliver more universally applicable, potent immunotherapies for both solid tumors and blood cancers.
Target Audience
Primary customers are pharmaceutical and biotech companies developing oncology pipelines, as well as academic research groups seeking novel immunotherapy candidates for solid and hematologic cancers.
Features
- Bispecific protein format that bridges tumor antigens with immune effector cells for targeted cytotoxicity
- CAR‑T cell constructs engineered to recognize the same shared cancer antigens, enabling cellular therapy across multiple indications
- Platform selection of antigens that are over‑expressed in virtually all cancer types but minimally present on normal tissues
- Modular design allowing rapid generation of new therapeutics against additional shared antigens
- Integrated preclinical validation pipeline to assess multi‑cancer efficacy and off‑target safety